Update on the European Medicines Agency recommendation not to renew Translarna marketingauthorisation in the European Union On Friday, 22 …
Update on the European Medicines Agency recommendation not to renew Translarna marketing
Action Duchenne Expresses Deep Concern Over CHMP’s Negative Opinion on Translarna™ for Duchenne Muscular Dystrophy
Action Duchenne Expresses Deep Concern Over CHMP's Negative Opinion on Translarna™ for Duchenne Muscular Dystrophy Action Duchenne expresses …
Introducing Science Live
Action Duchenne Launches Science Live Video Project Empowering Duchenne families, bringing research into your home We are thrilled to announce …
Online Event for Newly Diagnosed Families
Online Event for Newly Diagnosed Families Has your family had a recent Duchenne diagnosis? Are you feeling lost, alone and overwhelmed? Would you …
World Duchenne Awareness Day – An Open Letter to the Duchenne Community
World Duchenne Awareness Day - An Open Letter to the Duchenne Community To the International Duchenne Community World Duchenne Awareness Day is …
World Duchenne Awareness Day – An Open Letter to the Duchenne CommunityRead More
DMD Bone Health Information and Sharing Session
We are delighted to announce that Action Duchenne, together with MDUK, is co-hosting an event for Duchenne adults and carers. We are …
<strong>DMD Bone Health Information and Sharing Session</strong>Read More
Group Counselling
Group Counselling We know that being a Duchenne parent or carer is tough, and that a diagnosis like Duchenne impacts many of the relationships in …
An intervention for parents of boys with DMD is under development, please share your experiences and needs
We are developing an intervention for parents of boys with DMD and want to knowmore about your experiences and needs! If you are interested and want …
Edgewise Therapeutics Announces Positive 12-Month Topline Results From The ARCH Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy (BMD)
Edgewise Therapeutics announced today positive 12-month topline results from the ongoing ARCH study, an open label, single-center study assessing the …
Registration is OPEN for the Action Duchenne Annual International Conference 2023
Registration is OPEN for the Action Duchenne Annual International Conference 2023 FREE tickets for Duchenne families as well as every young …
Roche UK issues a statement following Sarepta’s Press release regarding ELEVIDYS FDA decision
Roche UK issues a statement following Sarepta's Press release regarding ELEVIDYS FDA decision Following the press release from Sarepta released on …
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene …
